U.S. markets open in 2 hours 25 minutes
  • S&P Futures

    4,213.00
    -0.75 (-0.02%)
     
  • Dow Futures

    33,746.00
    -15.00 (-0.04%)
     
  • Nasdaq Futures

    14,136.75
    +6.75 (+0.05%)
     
  • Russell 2000 Futures

    2,274.30
    -6.60 (-0.29%)
     
  • Crude Oil

    73.15
    -0.51 (-0.69%)
     
  • Gold

    1,785.80
    +2.90 (+0.16%)
     
  • Silver

    26.02
    -0.00 (-0.02%)
     
  • EUR/USD

    1.1899
    -0.0026 (-0.21%)
     
  • 10-Yr Bond

    1.4840
    0.0000 (0.00%)
     
  • Vix

    17.70
    -3.00 (-14.49%)
     
  • GBP/USD

    1.3882
    -0.0051 (-0.37%)
     
  • USD/JPY

    110.4480
    +0.1500 (+0.14%)
     
  • BTC-USD

    31,659.70
    -801.16 (-2.47%)
     
  • CMC Crypto 200

    757.80
    -92.55 (-10.88%)
     
  • FTSE 100

    7,078.35
    +16.06 (+0.23%)
     
  • Nikkei 225

    28,884.13
    +873.20 (+3.12%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of EBON, DDD and CCXI

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / May 7, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Ebang International Holdings Inc. (NASDAQ:EBON)
Class Period: June 26, 2020 - April 5, 2021
Lead Plaintiff Deadline: June 7, 2021

During the class period, Ebang International Holdings Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the proceeds from Ebang's public offerings had been directed to an low yield, long term bonds to an underwriter and to related parties rather than used to develop the Company's operations; (2) Ebang's sales were declining and the Company had inflated reported sales, including through the sale of defective units; (3) Ebang's attempts to go public in Hong Kong had failed due to allegations of embezzling investor funds and inflated sales figures; (4) Ebang's purported crytocurrency exchange was merely the purchase of an out-of-the-box crypto exchange; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in EBON: http://www.kleinstocklaw.com/pslra-1/ebang-international-holdings-inc-loss-submission-form?id=15599&from=1

3D Systems Corporation (NYSE:DDD)
Class Period: May 6, 2020 - March 1, 2021
Lead Plaintiff Deadline: June 8, 2021

The complaint alleges that during the class period 3D Systems Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) 3D Systems lacked proper internal controls over financial reporting; and (2) as a result, 3D Systems' public statements were materially false and/or misleading at all relevant times.

Learn about your recoverable losses in DDD: http://www.kleinstocklaw.com/pslra-1/3d-systems-corp-loss-submission-form?id=15599&from=1

ChemoCentryx, Inc. (NASDAQ:CCXI)
Class Period: November 26, 2019 - May 3, 2021
Lead Plaintiff Deadline: July 6, 2021

The CCXI lawsuit alleges ChemoCentryx, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in CCXI: http://www.kleinstocklaw.com/pslra-1/chemocentryx-inc-loss-submission-form?id=15599&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/645699/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-EBON-DDD-and-CCXI